Amgen Worldwide
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
オンラインリソース
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
疾患教育
重点領域
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
アムジェン株式会社（本社：東京、代表取締役社長：スザナ・ムルテイラ、以下「アムジェン」）は、循環器病対策の取り組みの一つとして、一般社団法人日本循環器協会（以下「日本循環器協会」）と共に急性冠症候群（ACS）再発予防のためのACSヘルスケアエコシステム形成プロジェクトを開始しました。本プロジェクトでは、日本循環器協会が主体となり、神奈川県におけるACSクリニカルパスの作成及び有用性の検証、並びに構築されたクリニカルパスの全国への啓発・展開を目指します。
日本循環器協会の代表理事である東京大学の小室一成名誉教授は次のように述べています。「ACSは生命に直結する疾患である一方、再発が大変多いことが知られています。ACSになった方の再発予防は急務であり、全国でクリニカルパスの構築が進みつつありますが、作成・更新の進捗には地域差があります。実態の的確な把握に基づき、より良いACS再発予防のモデルを提唱していきたいと考えています」
ACSなどの虚血性心疾患は心不全を引き起こす原因の一つで、全心不全患者の３割を占めます。超高齢社会を迎えた日本において心不全患者は増え続けており、2030年には130万人に達すると推計されています。心不全になると身体機能の低下、それに伴う労働生産性の低下、介護者の精神・身体的負担などにつながることからも、ACS患者の再発予防対策は重要です。
急性冠動脈症候群（ACS）について
急性冠症候群 （ACS：Acute Coronary
Syndrome）とは、冠動脈の血管が狭くなったり、詰まったりすることにより、心筋組織に十分な血液が供給されなくなることで引き起こされる症候群のことです。急性心筋梗塞、不安定狭心症、虚血による心臓突然死が含まれます。
一般社団法人日本循環器協会について
一般社団法人日本循環器協会は循環器病対策基本法の施行をうけて、患者・企業・医療者をつなぐ架け橋となるプラットフォームの役割を果たすために2021年に設立された新しい団体です。日本循環器学会、日本心臓財団と緊密に連携をとりながら”もっと近くで”活動しています。詳細は以下のホームページなどからご覧ください。
ホームページ：https://j-circ-assoc.or.jp/
Facebook：https://www.facebook.com/J.Circ.Assoc
Twitter：https://twitter.com/J_Circ_Assoc
アムジェン株式会社について
アムジェン株式会社は、世界最大規模の独立バイオテクノロジー企業である米国アムジェン社の日本法人です。アムジェン株式会社では、循環器疾患、がん、骨疾患、炎症・免疫性疾患、神経疾患、希少疾患を始めとするアンメット・メディカル・ニーズが高い領域に焦点を絞り、「To
serve patients – 患者さんのために、今できるすべてを」というミッションのもと、臨床開発から販売までの活動を行っています。詳細については
https://www.amgen.co.jp をご覧になるか、https://www.facebook.com/amgenjapan
をフォローしてください。
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of
Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking
statements, including any statements on the outcome, benefits and synergies of collaborations, or potential
collaborations, with any other company (including BeiGene, Ltd. or Kyowa-Kirin Co., Ltd.), the performance of
Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS
accretion), the Teneobio, Inc. acquisition, the ChemoCentryx, Inc. acquisition, or the Horizon Therapeutics plc
acquisition (including the prospective performance and outlook of Horizon’s business, performance and opportunities
and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well
as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal,
arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices,
reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business,
outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and
uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission
reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on
Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the
date of this news release and does not undertake any obligation to update any forward-looking statements contained
in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project.
Discovery or identification of new product candidates or development of new indications for existing products cannot
be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any
particular product candidate or development of a new indication for an existing product will be successful and
become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product
candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical
trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability
in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for
approval of the trial endpoints we have selected. We develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be
subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at
the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing
problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such acquisition or integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Further, any scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.
注意事項（アムジェン株式会社）
このニュースリリースに含まれている医薬品（開発中のものを含む）に関する情報は、宣伝広告、医学的アドバイスを目的とするものではありません。
###
この件に関するお問い合わせ先
アムジェン株式会社（東京）
コーポレート・アフェアーズ
TEL：03-4520-2447